Cytotoxicity and pro‐apoptosis activity of synthetic ۱,۳-thiazole incorporated phthalimide derivatives on cancer cells

سال انتشار: 1400
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 163

فایل این مقاله در 11 صفحه با فرمت PDF قابل دریافت می باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-24-5_006

تاریخ نمایه سازی: 18 اردیبهشت 1400

چکیده مقاله:

Objective(s): Cancer is the second important reason for death worldwide. In spite of advances in cancer treatment, however, survival of patients stays weak. Therefore, there is a critical need for advancement of new anticancer drugs. Regarding the hopeful biological activity of phthalimide derivatives, in this study, synthesis, cytotoxicity, and pro‐apoptosis activity of eleven derivatives of thiazole bearing phthalimide structure were evaluated.Materials and Methods: First, target derivatives were synthesized. All synthesized compounds were characterized by spectroscopic methods. Cytotoxicity and pro‐apoptosis activity of the synthesized compounds were evaluated in MDA-MB-۴۶۸, PC-۱۲, and MCF-۷ cancer cell lines by MTT assay, caspase-۳ activity, and TUNEL assay. Finally, expression of BAX, BCL-۲, and FAS (as markers of apoptosis) was assessed by the RT-PCR procedure.Results: Among the eleven compounds, ۵b (IC۵۰ = ۰.۲±۰.۰۱ µM) was found to be the most potent derivative against MCF-۷ cells. Also, Compound ۵k and ۵g showed strong cytotoxic activity against MDA-MB-۴۶۸ and PC-۱۲ cells with IC۵۰ value of ۰.۶±۰.۰۴ µM and ۰.۴۳±۰.۰۶ µM, respectively.  DNA fragmentation and activity of caspase-۳ data suggest that cytotoxic activity of the compounds on cancer cells might be related to apoptosis. Also, RT-PCR of apoptosis markers indicated that these compounds induce apoptosis through the intrinsic pathway.Conclusion: Our findings suggest that para chloro derivative (۵c) may be a promising agent for treatment of cancer cells by the targeted intrinsic pathway of apoptosis and could be used as a drug candidate for in vivo assessment in the treatment of cancer.

نویسندگان

Omid Tavallaei

Pharmaceutical Sciences Research Center, Health Institute, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

Milad Heidarian

Department of Pharmacognosy and Pharmaceutical Biotechnology, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

Marzieh Marzbany

Pharmaceutical Sciences Research Center, Health Institute, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

Alireza Aliabadi

Pharmaceutical Sciences Research Center, Health Institute, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1. Jemal A. Murray t. Ward E, Samuels A, Tiwari ...
  • 2. Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanuja ...
  • 3. Leite AC, Santos LM, Moreira DR, Brondani DJ. Synthesis ...
  • 4. Ferreira PM, Lima DJ, Debiasi BW, Soares BM, da ...
  • 5. Ferreira JR, Cavalcanti BC, da Costa PM, de Arantes ...
  • 6. Ruchelman AL, Man HW, Zhang W, Chen R, Capone ...
  • 7. Aliabadi A, Gholamine B, Karimi T, Synthesis and antiseizure ...
  • 8. Mohammadi-Farani A, Abdi N, Moradi A, Aliabadi A, 2-(2-(4-Benzoylpiperazin-1-yl)ethyl)isoindoline-1,3-dione ...
  • 9. Aliabadi A, Foroumadi A, Safavi M, Kaboudian Ardestani S, ...
  • 10. Aliabadi A, Mohammadi-Farani A, Seydi-Kangarshahi S, Ahmadi F, Discovery ...
  • 11. Machado AL, Lima LM, Araújo-Jr JX, Fraga CA, Koatz ...
  • 12. Mazzoccoli L, Cadoso SH, Amarante GW, de Souza MV, ...
  • 13. Yang YJ, Yang YN, Jiang JS, Feng ZM, Liu ...
  • 14. Akgün H, Karamelekoğlu İ, Berk B, Kurnaz I, Sarıbıyık ...
  • 15. Andrade P, Visser-Vandewalle V, Del Rosario JS, Daemen MA, ...
  • 16. Palencia G, Rubio C, Custodio-Ramirez V, Paz C, Sotelo ...
  • 17. Pessoa C, Ferreira PM, Lotufo LV, de Moraes MO, ...
  • 18. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide ...
  • 19. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu ...
  • 20. Badamtseren B, Odkhuu E, Koide N, Haque A, Naiki ...
  • 21. Kagoya Y, Nannya Y, Kurokawa M. Thalidomide maintenance therapy ...
  • 22. Hosseinzadeh L, Aliabadi A, Kalantari M, Mostafavi A, Rahmani ...
  • 24. Hosseinzadeh L, Aliabadi A, Rahnama M, Mir Mohammad Sadeghi ...
  • 26. Aliabadi A, Foroumadi A, Safavi M, K. Ardestani S, ...
  • 27. Mohammadi-Farani A, Foroumadi A, Rezvani Kashani M, Aliabadi A, ...
  • 28. Yang Y, Zhu YQ, Jiang L, Li LF, Ge ...
  • 29. Nabhan C, Petrylak DP. The role of IMiDs alone ...
  • 30. Macpherson GR, Franks M, Tomoaia-Cotisel A, Ando Y, Price ...
  • 31. Silva Júnior JG, Holanda VN, Rodrigues Gamb DS, Siqueira ...
  • 32. Huang P, Robertson LE, Wright S, Plunkett W. High ...
  • 33. Safavi M, Esmati N, Ardestani SK, Emami S, Ajdari ...
  • 34. Lu Y, Mahato RI, editors. Pharmaceutical perspectives of cancer ...
  • 35. Xie K, Huang S. Contribution of nitric oxide-mediated apoptosis ...
  • 36. Mahdavi M, Davoodi J, Zali MR, Foroumadi A. Concomitant ...
  • 37. Elmore S. Apoptosis: a review of programmed cell death. ...
  • 38. Cáceres-Castillo D, M. Carballo R, A. Tzec-Interián J, J. ...
  • 39. Mohammadi G, Shakeri A, Fattahi A, Mohammadi P, Mikaeili ...
  • 41. Rahmani-Khajouei M, Mohammadi-Farani A, Moradi A, Aliabadi A, Synthesis ...
  • 42. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic ...
  • 43. Nakamura S, Kobayashi M, Shibata K, Sahara N, Shigeno ...
  • 44. Brady HJ, Gil-Gomez G. The pro-apoptotic Bcl-2 family member, ...
  • 45. Nagata S, Golstein P. The Fas death factor. Science ...
  • 46. Nagata S. Apoptosis by death factor. Cell 1997; 88:355-365 ...
  • 47. Tanaka M, Suda T, Takahashi T, Nagata S. Expression ...
  • 48. Suda T, Takahashi T, Golstein P, Nagata S. Molecular ...
  • 49. Xerri L, Devilard E, Hassoun J, Mawas C, Birg ...
  • 50. Poppema S, Potters M, Visser L, Van den Berg ...
  • 51. Bennett MW, O’Connell J, O’Sullivan GC, Roche D, Brady ...
  • 52. Lee SH, Shin MS, Park WS, Kim SY, Dong ...
  • 53. Loreto C, La Rocca G, Anzalone R, Caltabiano R, ...
  • نمایش کامل مراجع